J1590 — Injection, gatifloxacin, 10 mg
J1590 is a HCPCS Level II code for injection, gatifloxacin, 10 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2016 and is not valid on new claims.
This code has been terminated
CMS terminated J1590 on December 31, 2016. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J1590
- Long descriptor
- Injection, gatifloxacin, 10 mg
- Short descriptor
- Gatifloxacin injection
- Added
- January 1, 2002
- Terminated
- December 31, 2016
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J1590
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J1590 is not quite right, the correct code is very often within a few positions of it.
- J1571Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml
- J1572Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1573Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml
- J1574Injection, ganciclovir sodium (exela), not therapeutically equivalent to j1570, 500 mg
- J1575Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin
- J1576Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1577Injection, immune globulin (qivigy), 100 mg
- J1580Injection, garamycin, gentamicin, up to 80 mg
- J1595Injection, glatiramer acetate, 20 mg
- J1596Injection, glycopyrrolate, 0.1 mg
- J1597Injection, glycopyrrolate (glyrx-pf), 0.1 mg
- J1598Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
- J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg
- J1600Injection, gold sodium thiomalate, up to 50 mg
- J1602Injection, golimumab, 1 mg, for intravenous use
- J1610Injection, glucagon hydrochloride, per 1 mg
Questions about J1590
What is HCPCS code J1590?
J1590 is a HCPCS Level II code for injection, gatifloxacin, 10 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J1590?
The CMS HCPCS file marks J1590 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J1590 still valid?
No. J1590 was terminated on December 31, 2016 and should not be used on new claims.